KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Profit After Tax (2016 - 2025)

Jazz Pharmaceuticals has reported Profit After Tax over the past 16 years, most recently at $203.5 million for Q4 2025.

  • Quarterly Profit After Tax rose 6.45% to $203.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$356.1 million through Dec 2025, down 163.58% year-over-year, with the annual reading at -$356.1 million for FY2025, 163.58% down from the prior year.
  • Profit After Tax was $203.5 million for Q4 2025 at Jazz Pharmaceuticals, down from $251.4 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $251.4 million in Q3 2025 and troughed at -$718.5 million in Q2 2025.
  • The 5-year median for Profit After Tax is $52.0 million (2022), against an average of $3.3 million.
  • Biggest five-year swings in Profit After Tax: crashed 580.95% in 2022 and later soared 4114.94% in 2023.
  • Tracing JAZZ's Profit After Tax over 5 years: stood at -$35.4 million in 2021, then crashed by 580.95% to -$240.7 million in 2022, then soared by 139.11% to $94.2 million in 2023, then soared by 102.98% to $191.1 million in 2024, then grew by 6.45% to $203.5 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at $203.5 million, $251.4 million, and -$718.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.